What Are the Implications of the Cough Syrup Deaths? ED Raids 7 Locations in Chennai Linked to Sresan Pharma
Click to start listening
Synopsis
The ED's investigation into Sresan Pharmaceuticals highlights serious safety violations and potential fraud linked to the tragic cough syrup deaths of 22 children. With extensive searches underway, the case raises alarming questions about regulatory oversight in the pharmaceutical industry.
Key Takeaways
- Enforcement Directorate conducts searches at multiple locations in Chennai.
- Owner of Sresan Pharmaceuticals, G. Ranganathan, arrested amid investigations.
- Over 300 regulatory violations uncovered at the manufacturing plant.
- Cough syrup tested positive for 48.6% diethylene glycol (DEG).
- Raids aim to uncover potential financial misconduct and collusion.
Chennai, Oct 13 (NationPress) The Enforcement Directorate (ED) commenced searches at seven different sites in Chennai on Monday. This includes the residence of S. Ranganathan, the proprietor of Sresan Pharmaceuticals, along with offices belonging to senior officials from the Tamil Nadu Drug Control Department. These actions are part of an investigation into potential money laundering under the Prevention of Money Laundering Act (PMLA).
This operation follows a significant development in the Madhya Pradesh cough syrup incident, where at least 22 children tragically lost their lives after ingesting the company's Coldrif cough syrup.
The ED's scrutiny is a continuation of events after the arrest of Sresan Pharmaceuticals’ owner, G. Ranganathan (75), who was apprehended by a Special Investigation Team (SIT) from Madhya Pradesh, aided by Chennai Police on October 9. Ranganathan, who had been evading authorities since the reported fatalities, was located through electronic surveillance and taken into custody during a late-night operation around 1:30 a.m. at his residence in Kodambakkam.
In the wake of his arrest, police teams conducted raids at the company’s manufacturing facility in Kancheepuram, where they seized critical production records, drug samples, and regulatory documents.
Investigations have unveiled over 300 safety and regulatory breaches at the plant, including the use of non-pharmaceutical grade chemicals. Laboratory analyses confirmed that the cough syrup contained 48.6 percent diethylene glycol (DEG), a highly hazardous industrial solvent known to induce irreversible kidney failure upon ingestion.
Officials are investigating the possibility that inferior quality ingredients were intentionally utilized to reduce production costs, resulting in the contamination.
This operation signifies the third major ED intervention against pharmaceutical companies in Chennai recently.
In September, the agency conducted raids on multiple sites linked to Arvind Remedies Ltd concerning a Rs 637-crore bank loan fraud. Earlier in April 2024, the ED had searched 30 locations across Tamil Nadu related to the Jaffer Sadiq drug trafficking and money laundering investigation, revealing an international narcotics network.
The current raids aim to uncover potential financial misconduct, fund diversion, and regulatory collusion between Sresan Pharmaceuticals and state drug control officials.
Sources indicate that the ED is also exploring whether illicit funds were laundered through shell companies and benami accounts associated with Ranganathan’s network.
As the ED intensifies its inquiry, further arrests are anticipated as investigators unravel the financial and administrative failures that have led to one of the nation's recent pharmaceutical calamities.
Point of View
NationPress recognizes the gravity of the situation surrounding the cough syrup deaths in Madhya Pradesh. The ongoing ED investigation underscores the critical need for stringent regulations in the pharmaceutical industry. Transparency and accountability are paramount to prevent such tragedies in the future.
NationPress
13/10/2025
Frequently Asked Questions
What triggered the ED's investigation into Sresan Pharmaceuticals?
The ED's investigation was initiated following the tragic deaths of 22 children in Madhya Pradesh linked to the company's cough syrup. This raised concerns about potential regulatory violations and financial misconduct.
What were the findings from the raids conducted by the ED?
The ED discovered over 300 safety and regulatory violations at the Sresan Pharmaceuticals plant, including the use of hazardous chemicals in their cough syrup.
What is diethylene glycol (DEG) and why is it dangerous?
Diethylene glycol (DEG) is a toxic industrial solvent that can cause serious health issues, including irreversible kidney failure when ingested, making its presence in cough syrup extremely concerning.
How has the ED's investigation evolved over time?
The investigation has expanded following the arrest of G. Ranganathan, revealing potential collusion between pharmaceutical companies and regulatory bodies, and leading to multiple raids across Chennai.
What broader implications does this case have for the pharmaceutical industry?
This case highlights serious regulatory lapses within the pharmaceutical industry, emphasizing the urgent need for reforms to ensure the safety and efficacy of medications available to the public.
